Minocycline
Major Depressive Disorder
Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Stony Brook University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06699966CT.gov Stony Brook Medicine Anti-Inflammatory Trial | — | Not Yet Recruiting | — | — | — |
NCT06537921CT.gov Comorbid Obesity and Depression With an Anti-inflammatory Medication | — | Recruiting | — | — | — |
NCT05644301CT.gov INflammation-based Stratification for Immune-Targeted Augmentation in Major Depressive Disorder | — | Recruiting | — | — | — |
NCT03947827CT.gov Minocycline as Adjunctive Treatment for Treatment Resistant Depression | — | Completed | — | — | — |
NCT02362529CT.gov Biomarkers of Neuroinflammation and Anti-Inflammatory Treatments in Major Depressive Disorder | — | Completed | — | — | — |
NCT02456948CT.gov Adjunct Minocyline in Treatment-resistant Depression | — | Completed | — | — | — |
NCT01574742CT.gov Open Study Assessing the Feasibility of Minocycline in Patients With Unipolar Depression | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Major Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Minocycline (this asset) | Stony Brook University | Approved | BB · 64 |
| Selegiline | Corium Innovations, Inc. | P4 | BBB |
| Risperidone | Johns Hopkins University | P4 | BBB |
| Edivoxetine | Eli Lilly and Company | P3 | BBB |
| (1S,2R)-MILNACIPRAN | Allergan | P4 | BBB |
| Vortioxetine | Mayo Clinic | P4 | BBB |
| Brexpiprazole | Nova Scotia Health Authority | P4 | BBB |
| Amitriptyline | e-Therapeutics PLC | P4 | BBB |
| 17.BETA.-(1-KETOETHYL)-.DELTA. SUP(5)-ANDROSTEN-3.BETA.-OL | Massachusetts General Hospital | P4 | BBB |
+42 more in the Major Depressive Disorder cohort
Other indications for Minocycline
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mood Disorder | — | P4 | BBB · 73 |
| Bipolar Depression | — | P4 | BB · 70 |
| Schizophrenia | — | P4 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Minocycline in Major Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/minocycline-major-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →